<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">SCIENCE</journal-id>
<journal-title>Science</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Science</abbrev-journal-title>
<issn pub-type="ppub">0036-8075</issn><issn pub-type="epub">1095-9203</issn>
<publisher><publisher-name>American Association for the Advancement of Science</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1235214</article-id>
<article-id pub-id-type="doi">10.1126/science.1235214</article-id>
<article-categories>
<subj-group subj-group-type="article-type"><subject>Report</subject></subj-group>
<subj-group subj-group-type="heading"><subject>Reports</subject></subj-group>
<subj-group subj-group-type="legacy-article-type"><subject>reports</subject></subj-group>
<subj-group subj-group-type="field"><subject>IMMUNOLOGY</subject></subj-group>
<subj-group subj-group-type="display-ad"><subject>Virology</subject><subject>Immunology</subject><subject>Physiology</subject></subj-group>
</article-categories>
<title-group>
<article-title>Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Teijaro</surname><given-names>John R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="fn" rid="afn1">*</xref></contrib> <contrib contrib-type="author"><name><surname>Ng</surname><given-names>Cherie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="fn" rid="afn1">*</xref></contrib> <contrib contrib-type="author"><name><surname>Lee</surname><given-names>Andrew M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="fn" rid="afn2">&#x2020;</xref></contrib> <contrib contrib-type="author"><name><surname>Sullivan</surname><given-names>Brian M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib> <contrib contrib-type="author"><name><surname>Sheehan</surname><given-names>Kathleen C. F.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib> <contrib contrib-type="author"><name><surname>Welch</surname><given-names>Megan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib> <contrib contrib-type="author"><name><surname>Schreiber</surname><given-names>Robert D.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib> <contrib contrib-type="author"><name><surname>Carlos de la Torre</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib> <contrib contrib-type="author" corresp="yes"><name><surname>Oldstone</surname><given-names>Michael B. A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">&#x2021;</xref></contrib>
<aff id="aff1"><label>1</label>Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.</aff>
<aff id="aff2"><label>2</label>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</aff>
</contrib-group>
<author-notes>
<fn id="afn1" fn-type="equal"><label>*</label>
<p>These authors contributed equally to this work.</p></fn>
<fn id="afn2" fn-type="present-address"><label>&#x2020;</label>
<p>Present address: Center for Genetics of Host Defense, Immunology, University of Texas Southwestern, Dallas, TX 75390&#x2013;8505, USA.</p></fn>
<corresp id="cor1"><label>&#x2021;</label>Corresponding author. E-mail: <email xlink:href="mbaobo@scripps.edu">mbaobo@scripps.edu</email></corresp></author-notes>
<pub-date pub-type="ppub"><day>12</day><month>04</month><year>2013</year></pub-date>
<volume>340</volume>
<issue>6129</issue>
<fpage>207</fpage>
<lpage>211</lpage>
<history><date date-type="received"><day>15</day><month>01</month><year>2013</year></date><date date-type="accepted"><day>28</day><month>02</month><year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2013, American Association for the Advancement of Science</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder>American Association for the Advancement of Science</copyright-holder>
</permissions>
<abstract abstract-type="editor"><title>INTERFER(ON)ing Persistence</title><p>During persistent viral infections, a dysregulated immune response fails to control the infection. <bold>Wilson <italic>et al.</italic></bold> (p. <related-article related-article-type="in-this-issue" vol="340" issue="6129" page="202">202</related-article>) and <bold>Teijaro <italic>et al.</italic></bold> (p. <related-article related-article-type="in-this-issue" vol="340" issue="6129" page="207">207</related-article>; see the Perspective by <bold><related-article related-article-type="in-this-issue" vol="340" page="155" issue="6129">Odorizzi and Wherry</related-article></bold>) show this occurs because type I interferons (IFN I), critical for early responses to viral infection, contribute to the altered immunity seen during persistent infection. Antibody blockade of IFN I signaling during chronic lymphocytic choriomeningitis virus (LCMV) in mice resulted in reduced viral titers at later stages of infection, reduced expression of inhibitory immune molecules and prevented the disruptions to secondary lymphoid organs typically observed during persistent infection with LCMV. Whether type I IFNs are also detrimental to persistent viral infection humans, such as HIV and hepatitis C virus, remains to be determined.</p></abstract>
<abstract abstract-type="teaser"><p>Blockade of type I interferons leads to better control of persistent lymphocytic choriomeningitis virus infection. <named-content content-type="related-content">[Also see Perspective by <related-article related-article-type="in-this-issue" vol="340" page="155" issue="6129">Odorizzi and Wherry</related-article>]</named-content></p></abstract>
<abstract>
<p>During persistent viral infections, chronic immune activation, negative immune regulator expression, an elevated interferon signature, and lymphoid tissue destruction correlate with disease progression. We demonstrated that blockade of type I interferon (IFN-I) signaling using an IFN-I receptor neutralizing antibody reduced immune system activation, decreased expression of negative immune regulatory molecules, and restored lymphoid architecture in mice persistently infected with lymphocytic choriomeningitis virus. IFN-I blockade before and after establishment of persistent virus infection resulted in enhanced virus clearance and was CD4 T cell&#x2013;dependent. Hence, we demonstrate a direct causal link between IFN-I signaling, immune activation, negative immune regulator expression, lymphoid tissue disorganization, and virus persistence. Our results suggest that therapies targeting IFN-I may help control persistent virus infections.</p>
</abstract>
<custom-meta-wrap><custom-meta><meta-name>Editor</meta-name><meta-value>Kristen Mueller</meta-value></custom-meta><custom-meta><meta-name>Copyeditor</meta-name><meta-value>Trista Wagoner</meta-value></custom-meta></custom-meta-wrap></article-meta>
</front>
<body>
<p>Persistent viral infections such as HIV, hepatitis B virus, and hepatitis C virus (HCV) represent important global health problems. Persistent viruses take advantage of negative immune regulatory molecules to suppress antiviral CD4 and CD8 T cell responses (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="R2"><italic>2</italic></xref>), resulting in T cell exhaustion (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="R4"><italic>4</italic></xref>) and facilitating virus persistence. Hyperimmune activation is also observed after persistent virus infection and is characterized by prolonged activation of T cells, B cells, and natural killer (NK) cells; elevated pro-inflammatory mediators; and a sustained interferon signature (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>&#x2013;<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>). Type I interferon (IFN-I) signaling is upstream of hundreds of inflammatory genes, suggesting that IFN-I may be responsible for generating the hyperactivated immune environment during virus persistence. We investigated the role of IFN-I in regulating immune activation, immune suppression, and virus control after persistent virus infection in mice.</p>
<p>To elucidate the role of IFN-I in virus persistence, we used lymphocytic choriomeningitis virus (LCMV). In adult mice, the Armstrong (Arm) strain causes an acute infection that is cleared 8 days postinfection (dpi) because of robust antiviral CD8 T cell responses. In contrast to the Arm strain, the clone 13 (Cl13) strain causes a systemic viral infection lasting over 90 days (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>&#x2013;<xref ref-type="bibr" rid="R13"><italic>13</italic></xref>). Cl13-infected mice had significantly elevated IFN-I in the serum compared with Arm-infected counterparts at 18 and 24 hours postinfection (hpi) (<xref ref-type="fig" rid="F1">Fig. 1, A</xref> and B). By using IFN-&#x03B2;&#x2013;yellow fluorescent protein (YFP) reporter mice (<xref ref-type="bibr" rid="R14"><italic>14</italic></xref>), we detected YFP expression in plasmacytoid dendritic cells (pDCs) at 18 hours post&#x2013;Cl13 infection, with minimal YFP expression in pDCs during Arm infection (fig. S1A). IFN-&#x03B2;&#x2013;YFP expression was not observed in other splenocytes (fig. S1B), suggesting that Cl13 infection induces IFN-&#x03B2; production in pDCs. pDCs are reported to be an early target of Cl13 infection (<xref ref-type="bibr" rid="R13"><italic>13</italic></xref>, <xref ref-type="bibr" rid="R15"><italic>15</italic></xref>). To address whether Cl13 preferentially infected pDCs, we used nonreplicating Arm or Cl13 viruses, in which their glycoproteins (GPs) were replaced with a green fluorescent protein (GFP) marker (denoted &#x0394;GP-Cl13 or &#x0394;GP-Arm). As expected, pDCs exhibited a 2- to 2.5-fold increase in GFP expression upon infection with &#x0394;GP-Cl13 compared with &#x0394;GP-Arm (<xref ref-type="fig" rid="F1">Fig. 1C</xref>). Consistent with IFN-I signaling being upstream of inflammatory gene expression, we observed elevated expression of multiple pro-inflammatory cytokines and chemokines 18 hours post-Cl13 infection versus Arm infection (fig. S1C). To determine whether elevated pro-inflammatory cytokines and chemokines in Cl13 infection were due to IFN-I signaling, we treated mice with an antibody against interferon alpha-beta receptor 1 (anti-IFNAR1) before infection and measured cytokine and chemokine levels in the serum 18, 24, and 48 hpi (<xref ref-type="bibr" rid="R16"><italic>16</italic></xref>). Blockade of IFN-I signaling significantly blunted production of multiple pro-inflammatory cytokines and chemokines after Cl13 infection at 18, 24, and 48 hpi (fig. S1, C to E).</p>
<fig id="F1" position="float" fig-type="figure"><label>Fig. 1</label><caption>
<title>IFN-I is elevated early after onset of persistent virus infection.</title>
<p>Serum levels of IFN-&#x03B2; (<bold>A</bold>) and IFN-&#x03B1; species (<bold>B</bold>) as measured by enzyme-linked immunosorbent assay (ELISA) after initiation of persistent Cl13 or acute Arm infections in mice at 18, 24, 48, 120, and 240 hpi in C57BL/6J mice. (<bold>C</bold>) pDCs are preferentially infected early after Cl13 infection. Percent of GFP-positive pDCs infected with &#x0394;GP-Cl13 or &#x0394;GP-ARM viruses 24 hpi. *<italic>P</italic> &lt; 0.05; ***<italic>P</italic> &lt; 0.005. Results are representative of two to three independent experiments and represent the SEM from three to five mice per group.</p>
</caption><graphic xlink:href="340_207_F1"></graphic></fig>
<p>We asked whether IFN-I signaling contributes to the Cl13-induced immunosuppressive state. The IFN-I signaling blockade resulted in significant suppression of interleukin-10 (IL-10) production 1 and 5 dpi (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). We also detected significant suppression of programmed cell death 1 ligand 1 (PD-L1) on both CD8&#x03B1;<sup>+</sup> and CD8&#x03B1;<sup>&#x2013;</sup> DCs 1 dpi (<xref ref-type="fig" rid="F2">Fig. 2B</xref>), which was retained 5 and 9 dpi in CD8&#x03B1;<sup>&#x2013;</sup> but not CD8&#x03B1;<sup>+</sup> DCs (<xref ref-type="fig" rid="F2">Fig. 2, C</xref> and D). Together, these results demonstrate that IFN-I signaling inhibits negative regulatory molecule expression. Because DCs are primary targets of Cl13 infection and DC infection is crucial for virus persistence (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="R17"><italic>17</italic></xref>, <xref ref-type="bibr" rid="R18"><italic>18</italic></xref>), we asked whether blockade of IFN-I signaling altered the DC compartment. IFN-I blockade increased virus nucleoprotein (NP) expression in DCs and macrophages 5 dpi (fig. S2C). Blockade of IFN-I signaling significantly increased both the frequency and number of CD8&#x03B1;<sup>&#x2013;</sup> and CD8&#x03B1;<sup>+</sup> DCs and macrophages (fig. S2A). Moreover, we observed a significant increase in DCs with an immune-stimulatory phenotype after blockade of IFN-I signaling (fig. S2B).</p>
<fig id="F2" position="float" fig-type="figure"><label>Fig. 2</label><caption>
<title>IFN-I signaling is essential for the expression of the negative immune regulators IL-10 and PD-L1 and lymphoid tissue disorganization after persistent virus infection.</title>
<p>Mice were treated with anti-IFNAR1 1 day before infection. (<bold>A</bold>) Serum levels of IL-10 as measured by ELISA on days 1, 5, and 9 after cl13 infection in C57BL/6J mice treated with either isotype control antibodies or anti-IFNAR1. (<bold>B</bold>) Mean fluorescent intensity (MFI) of PD-L1 expression as determined by flow cytometry on either LCMV viral antigen positive (VL-4<sup>+</sup>) or viral antigen negative (VL-4<sup>&#x2013;</sup>) splenic DCs 1 day after cl13 infection. (<bold>C</bold>) Representative histograms of PD-L1 expression as determined by flow cytometry on either infected or uninfected (shaded histograms) CD8&#x03B1;-negative DCs (left) or compiled PD-L1 expression (right) at day 5 after Cl13 infection. (<bold>D</bold>) Histogram of PD-L1 expression (left) and mean fluorescent intensity (right) as determined by flow cytometry on splenic CD8&#x03B1;-negative dendritic cells at day 9 after Cl13 infection. Histopathological and immunofluorescent analysis of spleens on days 9 (<bold>E</bold>) and 14 (<bold>F</bold>) after Cl13 infection from na&#x00EF;ve mice or mice infected with Cl13 and treated with isotype antibodies or anti-IFNAR1 as above. (Top) Hematoxylin and eosin (H&amp;E) histopathological analysis. (Middle) Staining for a stromal cell marker (ER-TR7, a marker for fibroblastic reticular cells) and T cells (CD3). (Bottom) B cell staining (B220). Images were taken with a 5&#x00D7; objective. Scale bars indicate 500 &#x03BC;m. **<italic>P</italic> &lt; 0.01; ***<italic>P</italic> &lt; 0.005. Results are representative of two independent experiments and represent the SEM from five mice per group.</p>
</caption><graphic xlink:href="340_207_F2"></graphic></fig>
<p>The regulation of IL-10 and PD-L1 expression by IFN-I led us to investigate how IFN-I affects the immune environment during persistent virus infection. IFN-I blockade before Cl13 infection resulted in increased splenocyte numbers in anti-IFNAR1 compared with control treated mice 9 dpi (fig. S3A). This correlated with significant increases in B cells, CD4 and CD8 T cells, NK cells, DCs, and macrophages (fig. S3, B and C). Although IFN-I blockade resulted in early inhibition of multiple pro-inflammatory cytokines and chemokines and negative immune regulatory molecules after Cl13 infection (<xref ref-type="fig" rid="F2">Fig. 2</xref> and fig. S1, C to E), we detected increases in IFN-&#x03B3; production 24 hpi (fig. S2D) and similar levels of pro-inflammatory cytokines and chemokines 5 dpi (fig. S3D).</p>
<p>Lymphoid architecture is integral to induction and maintenance of immune responses (<xref ref-type="bibr" rid="R19"><italic>19</italic></xref>&#x2013;<xref ref-type="bibr" rid="R23"><italic>23</italic></xref>). Cl13 infection resulted in severe lymphoid disorganization (<xref ref-type="bibr" rid="R23"><italic>23</italic></xref>) with indistinguishable marginal zones and follicular structures and scattered B and T cell zones 9 dpi (<xref ref-type="fig" rid="F2">Fig. 2E</xref>), which was more apparent at 14 dpi (<xref ref-type="fig" rid="F2">Fig. 2F</xref>). IFN-I blockade preserved splenic architecture, so that white pulp, follicle margins, and T and B cell zones appeared similar to na&#x00EF;ve spleens (<xref ref-type="fig" rid="F2">Fig. 2E</xref>, middle and bottom). Fibroblastic reticular cell staining (ER-TR7; <xref ref-type="fig" rid="F2">Fig. 2E</xref>, middle row) highlighted preservation of splenic organization and architecture after IFN-I blockade. These data demonstrate that IFN-I signaling contributes to splenic architecture disorganization during Cl13 infection.</p>
<p>We next asked whether blockade of IFN-I signaling altered control of Cl13. IFN-I blockade resulted in increased percentages of lymphocytes expressing LCMV viral antigen 24 hpi (fig. S2, C and D) and significantly higher Cl13 titers in the serum 10 dpi (<xref ref-type="fig" rid="F3">Fig. 3A</xref>), suggesting that anti-IFNAR1 antibody treatment blocked early antiviral effects of IFN-I. By 30 dpi, we observed significant reductions in Cl13 titers after IFN-I blockade (&gt;1.5 logs) compared with isotype control treated mice (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). By 40 dpi, IFN-I blockade resulted in significant reductions of viral titers in both serum and tissues (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). By 50 dpi, virus was undetectable in the serum after IFN-I blockade, whereas control mice retained &gt;3 logs of virus (fig. S4A), demonstrating that IFN-I blockade hastens clearance of Cl13 infection.</p>
<fig id="F3" position="float" fig-type="figure"><label>Fig. 3</label><caption>
<title>IFN-I signaling blockade controls persistent virus infection.</title>
<p>C57BL/6J mice were treated with either isotype control antibody or anti-IFNAR1 1 day before infection with Cl13 (<bold>A</bold> and <bold>B</bold>) or 10 days after Cl13 infection (<bold>C</bold> and <bold>D</bold>). (A) Serum viral titers determined by plaque assay at the indicated times postinfection. (B) Viral titers in serum or indicated tissues at day 40 after infection. (C and D) Mice were infected with Cl13 and, 10 dpi, treated with three doses of anti-IFNAR1 (500 &#x03BC;g on days 10 and 12 and 250 &#x03BC;g on day 14). The graphs illustrate serum titers of mice 50 dpi in the serum (C) and lung and liver (D). **<italic>P</italic> &lt; 0.01; ***<italic>P</italic> &lt; 0.005; #<italic>P</italic> = 0.07. Results are representative of more than five independent experiments and represent the SEM from five mice per group. PFU, plaque-forming units.</p>
</caption><graphic xlink:href="340_207_F3"></graphic></fig>
<p>IFN-I transcripts are detectable in DCs several weeks after Cl13 infection (<xref ref-type="bibr" rid="R24"><italic>24</italic></xref>). We postulated that blocking IFN-I signaling during an established Cl13 infection would result in faster viral clearance. After an initial spike in viral titers 20 dpi, we observed &gt;1-log reduction in serum viral titers in anti-IFNAR1 compared with isotype-treated mice by 40 dpi (fig. S4B). By 50 dpi, 75% of the anti-IFNAR1 treated mice had undetectable levels of virus, whereas 75% of control animals maintained &gt;3 logs of virus (<xref ref-type="fig" rid="F3">Fig. 3D</xref>). Analysis of virus in liver and lung 50 dpi revealed reductions in viral titers in both tissues after IFN-I blockade (<xref ref-type="fig" rid="F3">Fig. 3D</xref>). These results demonstrate the therapeutic potential of IFN-I signaling blockade.</p>
<p>We asked whether enhanced virus clearance after IFN-I blockade could be duplicated after Arm infection. IFN-I blockade during Arm infection resulted in significantly elevated viral titers in the serum compared to control mice (fig. S5A). Anti-IFNAR1 treated animals maintained &gt;3 logs of virus in serum 20 dpi (fig. S5B). Moreover, after IFN-I blockade, viral titers were detectable in lungs, kidneys, and brains 30 dpi, a time when virus was undetectable in tissues of control mice (fig. S5C). The inability to clear Arm correlated with reduced expansion, functional potential, and cytolytic capacity of LCMV-specific CD8 T cells (fig. S5, D to G) with minimal effects on LCMV-specific CD4 T cells (fig. S5H). Clearance of Arm infection relies solely on antiviral CD8 T cells; thus, inhibition of IFN-I antiviral effects coupled to abrogation of CD8 T-cell responses likely contributed to defective control of Arm infection.</p>
<p>To measure localization of na&#x00EF;ve T cells to T cell zones in the spleen, we adoptively transferred carboxyfluorescein diacetate succinimidyl ester (CFSE)&#x2013;labeled na&#x00EF;ve T cells into Cl13-infected mice treated with isotype antibodies or anti-IFNAR1. Na&#x00EF;ve T cells migrated to T cell zones in anti-IFNAR treated mice similar to na&#x00EF;ve controls 5 dpi. Although T cell zones were intact in isotype-treated mice, na&#x00EF;ve T cells did not remain in these areas (<xref ref-type="fig" rid="F4">Fig. 4, A</xref> and B) despite similar numbers of na&#x00EF;ve CFSE-labeled T cells in the spleen. At 14 dpi, differences in na&#x00EF;ve T cell localization between anti-IFNAR1 and isotype control treated mice were maintained (<xref ref-type="fig" rid="F4">Fig. 4B</xref>). Analysis of virus-specific T cell function revealed that the numbers of GP<sup>33</sup>-specific IFN-&#x03B3;<sup>+</sup> or IFN-&#x03B3;<sup>+</sup> tumor necrosis factor&#x2013;&#x03B1; (TNF-&#x03B1;<sup>+</sup>) IL-2<sup>+</sup> multifunctional cytokine-producing cells (<xref ref-type="fig" rid="F4">Fig. 4C</xref>) along with cytolytic potential (fig. S6A) after anti-IFNAR1 treatment were comparable to those in isotype control treated mice, whereas there was a significant decrease in IFN-&#x03B3;<sup>+</sup> TNF-&#x03B1;<sup>+</sup> GP33-specific CD8 T cells (<xref ref-type="fig" rid="F4">Fig. 4C</xref>). In contrast, GP61-specific IFN-&#x03B3;<sup>+</sup> and multifunctional CD4 T cells 9 dpi were elevated in anti-IFNAR1 compared with control treated mice (<xref ref-type="fig" rid="F4">Fig. 4D</xref>). Despite elevated numbers and enhanced functional potential of virus-specific CD4 T cells, we observed similar levels of LCMV-specific immunoglobulin G (IgG) in the serum (fig. S6B), demonstrating that IFN-I blockade enhances virus-specific CD4 T cell responses while maintaining antiviral CD8 T cell and antibody levels.</p>
<fig id="F4" position="float" fig-type="figure"><label>Fig. 4</label><caption>
<title>Control of persistent virus by IFN-I blockade correlates with altered T cell trafficking and requires CD4 T cells.</title>
<p>C57BL/6J mice were treated with isotype control antibody or anti-IFNAR1 before infection with CL13. (<bold>A</bold>) At 5 and 14 dpi, mice received adoptive transfers of CFSE-labeled na&#x00EF;ve T cells. Two hours after transfer, spleens were harvested to analyze homing and localization of na&#x00EF;ve T cells (green) to T cell zones [CD3, red; fibroblastic reticular cells (ER-TR7), blue]. Images were taken with a 20&#x00D7; objective. Scale bars, 100 &#x03BC;m. (<bold>B</bold>) Quantitation of na&#x00EF;ve T cell localization. The number of transferred CFSE-labeled na&#x00EF;ve T cells was counted in 10 random white pulp regions per spleen. (<bold>C</bold>) Total number of cytokine-producing GP<sub>33-41</sub> LCMV-specific CD8 T cells in the spleen on day 9 postinfection. (<bold>D</bold>) Total number of cytokine-producing GP<sub>61-80</sub> LCMV-specific CD4 T cells in the spleen on day 9 postinfection. (<bold>E</bold> to <bold>G</bold>) Mice treated with anti-CD4 and/or anti-IFNAR1 or control antibodies were infected with 2 &#x00D7; 10<sup>6</sup> PFU of Cl13, and viral titers were measured in the serum and tissues at the indicated times postinfection. Viral titers in the serum were quantified by plaque assay on days 14, 21, and 40 (E) and 50 (F) in the serum. (G) Viral titers in the lung, kidney, and brain in CD4-depleted mice treated with isotype or anti-IFNAR1 on day 75 postinfection. n.s., not significant; *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01; ***<italic>P</italic> &lt; 0.005. Results are representative of two independent experiments and represent SEM from four or five mice per group.</p>
</caption><graphic xlink:href="340_207_F4"></graphic></fig>
<p>Because blockade of IFN-I signaling resulted in significantly elevated virus-specific CD4 T cell responses, we asked whether CD4 T cells were required for virus control after IFN-I blockade. Antibody depletion of CD4 T cells had little effect on anti-IFNAR1&#x2013;mediated reduction of viral titers on day 21 postinfection (<xref ref-type="fig" rid="F4">Fig. 4E</xref>); however, by 40 and 50 dpi, CD4 depletion completely abrogated the anti-IFNAR1&#x2013;mediated reduction in viral titers compared with CD4-sufficient, IFNAR1-treated mice (<xref ref-type="fig" rid="F4">Fig. 4, E</xref> and F). Anti-IFNAR1 treatment after CD4 depletion had no effect on controlling Cl13 replication in lungs, kidneys, and brains 75 dpi (<xref ref-type="fig" rid="F4">Fig. 4G</xref>). These data demonstrate CD4 T cells are required for enhanced control of persistent virus infection after IFN-I blockade.</p>
<p>We identify IFN-I signaling as essential for immune activation, up-regulation of negative immune regulators, lymphoid disorganization, and virus persistence. IFN-I has pleiotropic effects on multiple cellular processes. Aside from antiviral effects (<xref ref-type="bibr" rid="R25"><italic>25</italic></xref>), IFN-I signaling influences cell differentiation, proliferation, and apoptosis (<xref ref-type="bibr" rid="R26"><italic>26</italic></xref>). Further, multiple pro-inflammatory mediators are downstream of IFN-I signaling; thus, IFN-I can regulate multiple physiological processes. Despite discovery of IFN-I over 50 years ago (<xref ref-type="bibr" rid="R27"><italic>27</italic></xref>), its mechanisms of action with respect to immune modulation (<xref ref-type="bibr" rid="R25"><italic>25</italic></xref>) or antiviral activity (<xref ref-type="bibr" rid="R28"><italic>28</italic></xref>, <xref ref-type="bibr" rid="R29"><italic>29</italic></xref>) remain unsettled.</p>
<p>Chronic immune activation after HIV infection is documented, and suppression of this hyperactivated state may alleviate pathologies associated with HIV infection (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>). Disease after experimental simian immunodeficiency virus (SIV) infection in rhesus macaques correlates with elevated IFN-I and inflammatory signatures (<xref ref-type="bibr" rid="R30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="R31"><italic>31</italic></xref>). In contrast, SIV infection in sooty mangabeys and African green monkeys, which develop modest pathology despite similar viral loads as macaques, correlates with reduced IFN-I and inflammatory signatures (<xref ref-type="bibr" rid="R32"><italic>32</italic></xref>). Similar correlations with respect to reduced immune activation exist in HIV-infected elite controllers, although whether reduced immune activation follows better control of virus infection is debatable (<xref ref-type="bibr" rid="R33"><italic>33</italic></xref>, <xref ref-type="bibr" rid="R34"><italic>34</italic></xref>). Moreover, an elevated interferon signature is observed in HCV-infected patients despite limited control of virus replication and development of liver pathology (<xref ref-type="bibr" rid="R35"><italic>35</italic></xref>, <xref ref-type="bibr" rid="R36"><italic>36</italic></xref>). Thus, the IFN-I signaling pathway may be a viable target to control persistent viral infections.</p>
</body>
<back><app-group><app>
<title>Supplementary Materials</title><supplementary-material>
<p><ext-link ext-link-type="uri" xlink:href="http://www.sciencemag.org/cgi/content/full/340/6129/207/DC1">www.sciencemag.org/cgi/content/full/340/6129/207/DC1</ext-link></p>
<p>Materials and Methods</p>
<p>Figs. S1 to S6</p>
<p>Reference (<xref ref-type="bibr" rid="R37"><italic>37</italic></xref>)</p></supplementary-material></app></app-group>
<ref-list>
<title>References and Notes</title>
<ref id="R1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>D. G.</given-names></name><etal /></person-group>., 
<article-title>Interleukin-10 determines viral clearance or persistence in vivo</article-title>. <source>Nat. Med.</source> 
<volume>12</volume>, 
<fpage>1301</fpage> (<year>2006</year>). <pub-id pub-id-type="doi">10.1038/nm1492</pub-id><pub-id pub-id-type="pmid">17041596</pub-id></citation></ref>
<ref id="R2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>D. L.</given-names></name><etal /></person-group>., 
<article-title>Restoring function in exhausted CD8 T cells during chronic viral infection</article-title>. <source>Nature</source> 
<volume>439</volume>, 
<fpage>682</fpage> (<year>2006</year>). <pub-id pub-id-type="doi">10.1038/nature04444</pub-id><pub-id pub-id-type="pmid">16382236</pub-id></citation></ref>
<ref id="R3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>J. S.</given-names></name><name><surname>Cox</surname><given-names>M. A.</given-names></name><name><surname>Zajac</surname><given-names>A. J.</given-names></name></person-group>, 
<article-title>T-cell exhaustion: characteristics, causes and conversion</article-title>. <source>Immunology</source> 
<volume>129</volume>, 
<fpage>474</fpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1111/j.1365-2567.2010.03255.x</pub-id><pub-id pub-id-type="pmid">20201977</pub-id></citation></ref>
<ref id="R4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zajac</surname><given-names>A. J.</given-names></name><etal /></person-group>., 
<article-title>Viral immune evasion due to persistence of activated T cells without effector function</article-title>. <source>J. Exp. Med.</source> 
<volume>188</volume>, 
<fpage>2205</fpage> (<year>1998</year>). <pub-id pub-id-type="doi">10.1084/jem.188.12.2205</pub-id><pub-id pub-id-type="pmid">9858507</pub-id></citation></ref>
<ref id="R5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Appay</surname><given-names>V.</given-names></name><name><surname>Sauce</surname><given-names>D.</given-names></name></person-group>, 
<article-title>Immune activation and inflammation in HIV-1 infection: causes and consequences</article-title>. <source>J. Pathol.</source> 
<volume>214</volume>, 
<fpage>231</fpage> (<year>2008</year>). <pub-id pub-id-type="doi">10.1002/path.2276</pub-id><pub-id pub-id-type="pmid">18161758</pub-id></citation></ref>
<ref id="R6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J. J.</given-names></name><name><surname>Altfeld</surname><given-names>M.</given-names></name></person-group>, 
<article-title>Innate immune activation in primary HIV-1 infection</article-title>. <source>J. Infect. Dis.</source> 
<volume>202</volume> (<supplement>suppl. 2</supplement>), 
<fpage>S297</fpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1086/655657</pub-id><pub-id pub-id-type="pmid">20846036</pub-id></citation></ref>
<ref id="R7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>d&#x2019;Ettorre</surname><given-names>G.</given-names></name><name><surname>Paiardini</surname><given-names>M.</given-names></name><name><surname>Ceccarelli</surname><given-names>G.</given-names></name><name><surname>Silvestri</surname><given-names>G.</given-names></name><name><surname>Vullo</surname><given-names>V.</given-names></name></person-group>, 
<article-title>HIV-associated immune activation: from bench to bedside</article-title>. <source>AIDS Res. Hum. Retroviruses</source> 
<volume>27</volume>, 
<fpage>355</fpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1089/aid.2010.0342</pub-id><pub-id pub-id-type="pmid">21309730</pub-id></citation></ref>
<ref id="R8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sevilla</surname><given-names>N.</given-names></name><etal /></person-group>., 
<article-title>Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells</article-title>. <source>J. Exp. Med.</source> 
<volume>192</volume>, 
<fpage>1249</fpage> (<year>2000</year>). <pub-id pub-id-type="doi">10.1084/jem.192.9.1249</pub-id><pub-id pub-id-type="pmid">11067874</pub-id></citation></ref>
<ref id="R9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>R.</given-names></name><name><surname>Salmi</surname><given-names>A.</given-names></name><name><surname>Butler</surname><given-names>L. D.</given-names></name><name><surname>Chiller</surname><given-names>J. M.</given-names></name><name><surname>Oldstone</surname><given-names>M. B.</given-names></name></person-group>, 
<article-title>Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence</article-title>. <source>J. Exp. Med.</source> 
<volume>160</volume>, 
<fpage>521</fpage> (<year>1984</year>). <pub-id pub-id-type="doi">10.1084/jem.160.2.521</pub-id><pub-id pub-id-type="pmid">6332167</pub-id></citation></ref>
<ref id="R10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salvato</surname><given-names>M.</given-names></name><name><surname>Borrow</surname><given-names>P.</given-names></name><name><surname>Shimomaye</surname><given-names>E.</given-names></name><name><surname>Oldstone</surname><given-names>M. B.</given-names></name></person-group>, 
<article-title>Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence</article-title>. <source>J. Virol.</source> 
<volume>65</volume>, 
<fpage>1863</fpage> (<year>1991</year>).<pub-id pub-id-type="pmid">1840619</pub-id></citation></ref>
<ref id="R11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>C. F.</given-names></name><name><surname>Borrow</surname><given-names>P.</given-names></name><name><surname>de la Torre</surname><given-names>J. C.</given-names></name><name><surname>Oldstone</surname><given-names>M. B.</given-names></name></person-group>, 
<article-title>Virus-induced immunosuppression: kinetic analysis of the selection of a mutation associated with viral persistence</article-title>. <source>J. Virol.</source> 
<volume>68</volume>, 
<fpage>7367</fpage> (<year>1994</year>).<pub-id pub-id-type="pmid">7933120</pub-id></citation></ref>
<ref id="R12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>B. M.</given-names></name><etal /></person-group>., 
<article-title>Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> 
<volume>108</volume>, 
<fpage>2969</fpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1073/pnas.1019304108</pub-id><pub-id pub-id-type="pmid">21270335</pub-id></citation></ref>
<ref id="R13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergthaler</surname><given-names>A.</given-names></name><etal /></person-group>., 
<article-title>Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> 
<volume>107</volume>, 
<fpage>21641</fpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1073/pnas.1011998107</pub-id><pub-id pub-id-type="pmid">21098292</pub-id></citation></ref>
<ref id="R14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheu</surname><given-names>S.</given-names></name><name><surname>Dresing</surname><given-names>P.</given-names></name><name><surname>Locksley</surname><given-names>R. M.</given-names></name></person-group>, 
<article-title>Visualization of IFNbeta production by plasmacytoid versus conventional dendritic cells under specific stimulation conditions in vivo</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> 
<volume>105</volume>, 
<fpage>20416</fpage> (<year>2008</year>). <pub-id pub-id-type="doi">10.1073/pnas.0808537105</pub-id><pub-id pub-id-type="pmid">19088190</pub-id></citation></ref>
<ref id="R15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macal</surname><given-names>M.</given-names></name><etal /></person-group>., 
<article-title>Plasmacytoid dendritic cells are productively infected and activated through TLR-7 early after arenavirus infection</article-title>. <source>Cell Host Microbe</source> 
<volume>11</volume>, 
<fpage>617</fpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1016/j.chom.2012.04.017</pub-id><pub-id pub-id-type="pmid">22704622</pub-id></citation></ref>
<ref id="R16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>K. C.</given-names></name><etal /></person-group>., 
<article-title>Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection</article-title>. <source>J. Interferon Cytokine Res.</source> 
<volume>26</volume>, 
<fpage>804</fpage> (<year>2006</year>). <pub-id pub-id-type="doi">10.1089/jir.2006.26.804</pub-id><pub-id pub-id-type="pmid">17115899</pub-id></citation></ref>
<ref id="R17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sevilla</surname><given-names>N.</given-names></name><name><surname>McGavern</surname><given-names>D. B.</given-names></name><name><surname>Teng</surname><given-names>C.</given-names></name><name><surname>Kunz</surname><given-names>S.</given-names></name><name><surname>Oldstone</surname><given-names>M. B.</given-names></name></person-group>, 
<article-title>Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion</article-title>. <source>J. Clin. Invest.</source> 
<volume>113</volume>, 
<fpage>737</fpage> (<year>2004</year>).<pub-id pub-id-type="pmid">14991072</pub-id></citation></ref>
<ref id="R18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oldstone</surname><given-names>M. B.</given-names></name><name><surname>Campbell</surname><given-names>K. P.</given-names></name></person-group>, 
<article-title>Decoding arenavirus pathogenesis: essential roles for alpha-dystroglycan-virus interactions and the immune response</article-title>. <source>Virology</source> 
<volume>411</volume>, 
<fpage>170</fpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1016/j.virol.2010.11.023</pub-id><pub-id pub-id-type="pmid">21185048</pub-id></citation></ref>
<ref id="R19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x00FC;ller</surname><given-names>S.</given-names></name><etal /></person-group>., 
<article-title>Role of an intact splenic microarchitecture in early lymphocytic choriomeningitis virus production</article-title>. <source>J. Virol.</source> 
<volume>76</volume>, 
<fpage>2375</fpage> (<year>2002</year>). <pub-id pub-id-type="doi">10.1128/jvi.76.5.2375-2383.2002</pub-id><pub-id pub-id-type="pmid">11836415</pub-id></citation></ref>
<ref id="R20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>D. P.</given-names></name><etal /></person-group>., 
<article-title>Lymphotoxin-beta-deficient mice show defective antiviral immunity</article-title>. <source>Virology</source> 
<volume>260</volume>, 
<fpage>136</fpage> (<year>1999</year>). <pub-id pub-id-type="doi">10.1006/viro.1999.9811</pub-id><pub-id pub-id-type="pmid">10405365</pub-id></citation></ref>
<ref id="R21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suresh</surname><given-names>M.</given-names></name><etal /></person-group>., 
<article-title>Role of lymphotoxin alpha in T-cell responses during an acute viral infection</article-title>. <source>J. Virol.</source> 
<volume>76</volume>, 
<fpage>3943</fpage> (<year>2002</year>). <pub-id pub-id-type="doi">10.1128/JVI.76.8.3943-3951.2002</pub-id><pub-id pub-id-type="pmid">11907234</pub-id></citation></ref>
<ref id="R22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>M.</given-names></name><etal /></person-group>., 
<article-title>Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections</article-title>. <source>J. Clin. Invest.</source> 
<volume>121</volume>, 
<fpage>998</fpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1172/JCI45157</pub-id><pub-id pub-id-type="pmid">21393864</pub-id></citation></ref>
<ref id="R23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>M.</given-names></name><etal /></person-group>., 
<article-title>Lymphoid tissue damage in HIV-1 infection depletes na&#x00EF;ve T cells and limits T cell reconstitution after antiretroviral therapy</article-title>. <source>PLoS Pathog.</source> 
<volume>8</volume>, 
<fpage>e1002437</fpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1371/journal.ppat.1002437</pub-id><pub-id pub-id-type="pmid">22241988</pub-id></citation></ref>
<ref id="R24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hahm</surname><given-names>B.</given-names></name><name><surname>Trifilo</surname><given-names>M. J.</given-names></name><name><surname>Zuniga</surname><given-names>E. I.</given-names></name><name><surname>Oldstone</surname><given-names>M. B.</given-names></name></person-group>, 
<article-title>Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling</article-title>. <source>Immunity</source> 
<volume>22</volume>, 
<fpage>247</fpage> (<year>2005</year>). <pub-id pub-id-type="doi">10.1016/j.immuni.2005.01.005</pub-id><pub-id pub-id-type="pmid">15723812</pub-id></citation></ref>
<ref id="R25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stetson</surname><given-names>D. B.</given-names></name><name><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group>, 
<article-title>Type I interferons in host defense</article-title>. <source>Immunity</source> 
<volume>25</volume>, 
<fpage>373</fpage> (<year>2006</year>). <pub-id pub-id-type="doi">10.1016/j.immuni.2006.08.007</pub-id><pub-id pub-id-type="pmid">16979569</pub-id></citation></ref>
<ref id="R26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Platanias</surname><given-names>L. C.</given-names></name></person-group>, 
<article-title>Mechanisms of type-I- and type-II-interferon-mediated signalling</article-title>. <source>Nat. Rev. Immunol.</source> 
<volume>5</volume>, 
<fpage>375</fpage> (<year>2005</year>). <pub-id pub-id-type="doi">10.1038/nri1604</pub-id><pub-id pub-id-type="pmid">15864272</pub-id></citation></ref>
<ref id="R27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>A.</given-names></name><name><surname>Lindenmann</surname><given-names>J.</given-names></name></person-group>, 
<article-title>Virus interference. I. The interferon</article-title>. <source>Proc. R. Soc. Lond. B Biol. Sci.</source> 
<volume>147</volume>, 
<fpage>258</fpage> (<year>1957</year>). <pub-id pub-id-type="doi">10.1098/rspb.1957.0048</pub-id><pub-id pub-id-type="pmid">13465720</pub-id></citation></ref>
<ref id="R28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>J. W.</given-names></name><name><surname>Rice</surname><given-names>C. M.</given-names></name></person-group>, 
<article-title>Interferon-stimulated genes and their antiviral effector functions</article-title>. <source>Curr. Opin. Virol.</source> 
<volume>1</volume>, 
<fpage>519</fpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1016/j.coviro.2011.10.008</pub-id><pub-id pub-id-type="pmid">22328912</pub-id></citation></ref>
<ref id="R29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>J. W.</given-names></name><etal /></person-group>., 
<article-title>A diverse range of gene products are effectors of the type I interferon antiviral response</article-title>. <source>Nature</source> 
<volume>472</volume>, 
<fpage>481</fpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1038/nature09907</pub-id><pub-id pub-id-type="pmid">21478870</pub-id></citation></ref>
<ref id="R30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manches</surname><given-names>O.</given-names></name><name><surname>Bhardwaj</surname><given-names>N.</given-names></name></person-group>, 
<article-title>Resolution of immune activation defines nonpathogenic SIV infection</article-title>. <source>J. Clin. Invest.</source> 
<volume>119</volume>, 
<fpage>3512</fpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19959871</pub-id></citation></ref>
<ref id="R31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacquelin</surname><given-names>B.</given-names></name><etal /></person-group>., 
<article-title>Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response</article-title>. <source>J. Clin. Invest.</source> 
<volume>119</volume>, 
<fpage>3544</fpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19959873</pub-id></citation></ref>
<ref id="R32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bosinger</surname><given-names>S. E.</given-names></name><etal /></person-group>., 
<article-title>Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys</article-title>. <source>J. Clin. Invest.</source> 
<volume>119</volume>, 
<fpage>3556</fpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19959874</pub-id></citation></ref>
<ref id="R33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>S. G.</given-names></name><name><surname>Walker</surname><given-names>B. D.</given-names></name></person-group>, 
<article-title>Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy</article-title>. <source>Immunity</source> 
<volume>27</volume>, 
<fpage>406</fpage> (<year>2007</year>). <pub-id pub-id-type="doi">10.1016/j.immuni.2007.08.010</pub-id><pub-id pub-id-type="pmid">17892849</pub-id></citation></ref>
<ref id="R34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x00E1;ez-Ciri&#x00F3;n</surname><given-names>A.</given-names></name><name><surname>Pancino</surname><given-names>G.</given-names></name><name><surname>Sinet</surname><given-names>M.</given-names></name><name><surname>Venet</surname><given-names>A.</given-names></name><name><surname>Lambotte</surname><given-names>O.</given-names></name></person-group>, 
<article-title>HIV controllers: how do they tame the virus?</article-title> <source>Trends Immunol.</source> 
<volume>28</volume>, 
<fpage>532</fpage> (<year>2007</year>). <pub-id pub-id-type="doi">10.1016/j.it.2007.09.002</pub-id><pub-id pub-id-type="pmid">17981085</pub-id></citation></ref>
<ref id="R35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>A. I.</given-names></name><etal /></person-group>., 
<article-title>Genomic analysis of the host response to hepatitis C virus infection</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> 
<volume>99</volume>, 
<fpage>15669</fpage> (<year>2002</year>). <pub-id pub-id-type="doi">10.1073/pnas.202608199</pub-id><pub-id pub-id-type="pmid">12441396</pub-id></citation></ref>
<ref id="R36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guidotti</surname><given-names>L. G.</given-names></name><name><surname>Chisari</surname><given-names>F. V.</given-names></name></person-group>, 
<article-title>Immunobiology and pathogenesis of viral hepatitis</article-title>. <source>Annu. Rev. Pathol.</source> 
<volume>1</volume>, 
<fpage>23</fpage> (<year>2006</year>). <pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100230</pub-id><pub-id pub-id-type="pmid">18039107</pub-id></citation></ref>
<ref id="R37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borrow</surname><given-names>P.</given-names></name><name><surname>Evans</surname><given-names>C. F.</given-names></name><name><surname>Oldstone</surname><given-names>M. B.</given-names></name></person-group>, 
<article-title>Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression</article-title>. <source>J. Virol.</source> 
<volume>69</volume>, 
<fpage>1059</fpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7815484</pub-id></citation></ref>
</ref-list>
<ack>
<title>Acknowledgments</title><p>The authors thank D. Fremgen, C. Cubitt, N. Ngo, and S. Rice for technical excellence. Data reported in the manuscript are tabulated in the main paper and in the supplementary materials. This research was supported by NIH grant AI09484 (M.B.A.O.); National Cancer Institute grants NCI CA43059 (R.D.S.) and U54AI057160 to the Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (MRCE) (R.D.S. and M.B.A.O.); grants AI077719 and AI047140 (J.C.d.l.T.), postdoctoral training grants AI007354; and American Heart fellowships 11POST7430106 (J.R.T.), HL007195 (C.N.), and NS041219 (B.M.S.).</p>
</ack></back>
</article>